Ambys Medicines fetches $47m Series A extension

Ambys Medicines, a liver cell therapy platform, has secured a $47 million extension to its Series A financing, raising the total tally to $107 million.

Ambys Medicines, a liver cell therapy platform, has secured a $47 million extension to its Series A financing, raising the total tally to $107 million. Third Rock Ventures led the round with participation from other backers that included Takeda, Schroders Capital, Laurion Capital, Smilegate Investment, and Alexandria Venture Investments.

Source: Press Release